Final results of a phase II study of oral vinorelbine (NVBo) monotherapy in patients (pts) with advanced EGFR-positive non-small-cell lung cancer (NSCLC) after failure of EGFR-TKI in first line (NAVoTRIAL 2)

Category Primary study
JournalAnnals of Oncology
Year 2016
This article has no abstract
Epistemonikos ID: bf2adad332419d759eb0127ac7e0d0d118ee065e
First added on: Dec 20, 2022